Stabilized GLP1R agonists were approved for the treatment of type 2 diabetes in 2008 (ref. 4) and at higher doses for overweight and obesity in 2017 and 2018 (ref. 5). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.